PAM
ELDN icon

Paradigm Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Paradigm Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-109
Closed -$97K – 684
2016
Q2 		$97K Buy
+109
New +$120K 0.02% 459

Other funds holding ELDN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Asset Management's ELDN Position: Q3 2016 in Review

Paradigm Asset Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2016, closing a stake of 109 shares — an estimated $97K sold.

Paradigm Asset Management first reported a position in ELDN in Q2 2016 and held it in 1 quarter. The position peaked at $97K in Q2 2016. 44 funds tracked by Wall St. Rank hold ELDN as of Q3 2016.

  • Paradigm Asset Management reported no remaining Eledon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Paradigm Asset Management sold 109 Eledon Pharmaceuticals shares in Q3 2016, an estimated $97K.
  • Paradigm Asset Management first reported a position in Eledon Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Paradigm Asset Management's Eledon Pharmaceuticals position peaked at $97K in Q2 2016.
  • 44 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2016.

Based on Paradigm Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.